Saturday, 14 December 2013

This Time, FDA Panel Endorses Diabetes Drug Dapagliflozin

A US Food and Drug Advisory (FDA) panel has voted 10 to 1 in favor of approval for AstraZeneca and Bristol-Myers Squibb's diabetes drug dapagliflozin (Medscape)



No comments:

Post a Comment